TrialsgrambetaRCTs are beautiful

CREDENCE

2019

Canagliflozin and Renal Events in Diabetes with Established Nephropathy

In 4,401 patients with type 2 diabetes and albuminuric CKD on maximal RAS blockade, canagliflozin reduced the composite of ESKD, creatinine doubling or renal/CV death compared with placebo.

Result

Efficacy: ESKD, doubling of creatinine, or renal or CV deathHR 0.70 (95% CI 0.59-0.82) · P < 0.001

Below 1 favours canagliflozin, above 1 favours placebo.

Also reported: Heart-failure hospitalisation HR 0.61.

Original publication
Subtopic
SGLT2 inhibitors
Design
Double-blind RCT, stopped early
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Perkovic V, et al. N Engl J Med. 2019;380(24):2295-2306.doi 10.1056/NEJMoa1811744

Discussion & critique

First dedicated SGLT2-inhibitor renal-outcome trial; stopped early for efficacy. Limited to T2DM with macroalbuminuria.

Discussed in podcasts